TherapeuticsMD, Inc. TXMD
TherapeuticsMD, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.
Profitability & efficiency
Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | — | — | 100.0% | 98.0% | 45.5% | 75.4% | 87.2% | 83.0% | 84.3% | 78.4% |
| Operating margin | -145.3% | -347.1% | -654.6% | 1.7% | -3092.8% | -239.8% | -304.6% | -808.8% | -462.7% | -466.3% |
| Net margin | -18.8% | -123.9% | -789.4% | 160.1% | -6700.9% | -282.9% | -354.8% | -823.7% | -458.5% | -464.3% |
| FCF margin | — | — | — | — | -5547.1% | -246.1% | -338.7% | -664.8% | -454.3% | -359.3% |
| Return on assets | -1.5% | -5.6% | -23.7% | 123.8% | -101.7% | -101.1% | -66.2% | -62.6% | -53.7% | -63.1% |
| Return on equity | -2.1% | -8.0% | -35.1% | 318.7% | 184.2% | 148.0% | -1914.4% | -136.0% | -59.2% | -70.5% |
| Debt / equity | — | — | — | — | -2.01× | -1.92× | 21.15× | 0.75× | — | — |
| Current ratio | 3.02 | 2.37 | 1.72 | 1.18 | 0.47 | 2.17 | 3.93 | 4.55 | 10.48 | 9.30 |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.